Johnson & Johnson: Colorectal Neoplasms trials

The registry lists 10 Colorectal Neoplasms studies with Johnson & Johnson as lead sponsor. 4 are open to participants now and 1 have results posted.

Phase 1 5Phase 2 2Phase 3 4No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received ChemotherapyRecruitingNCT06750094Phase 3
• A Study of JNJ-89402638 for Metastatic Colorectal and Gastric CancersRecruitingNCT06663319Phase 1
• A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal CancerRecruitingNCT06662786Phase 3
• A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal CancerRecruitingNCT05379595Phase 1/2
• A Phase III Study of Xilonix in Patients With Advanced Colorectal CancerTerminatedNCT01767857Phase 3Results posted
• A Study of JNJ-64251330 in Participants With Familial Adenomatous PolyposisCompletedNCT05014360Phase 1
• Post-Trial Access for Guselkumab in Participants With Familial Adenomatous PolyposisNo longer availableNCT04948398
• A Study of Guselkumab in Participants With Familial Adenomatous PolyposisCompletedNCT03649971Phase 1
• A Phase 3 Study to Evaluate Xilonix as an Anticancer Therapy in Patients With Symptomatic Colorectal CancerCompletedNCT02138422Phase 3
• A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid TumorsCompletedNCT00841191Phase 1/2